November 16, 2017 02:52 PM EST

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

Michael Mezher

The FDA on Wednesday announced it has cleared a next-generation sequencing (NGS) test developed by Memorial Sloan Kettering Cancer Center that can detect 468 unique …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

Michael Mezher

Sign up to read this article for free.

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

FDA clears next-gen tu­mor se­quenc­ing test from Memo­r­i­al Sloan Ket­ter­ing

Michael Mezher

Sign up to read this article for free.

more like this

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Mer­ck KGaA will con­tin­ue to add a tar­iff sur­charge for US cus­tomers

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Sanofi touts $20B in­vest­ment in US over five years

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

Merck KGaA will continue to add a tariff surcharge for US customers

Hengrui, one of China's leading biotechs, anticipates $1.2B in proposed Hong Kong listing

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

Sanofi touts $20B investment in US over five years

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings